Distinguished in Chronic Myelomonocytic Leukemia (CMML)

Dr. Joshua F. Zeidner

Hematology Oncology | Hematology | Oncology
University Of North Carolina At Chapel Hill
101 Manning Dr, 
Chapel Hill, NC 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Distinguished in Chronic Myelomonocytic Leukemia (CMML)
University Of North Carolina At Chapel Hill
101 Manning Dr, 
Chapel Hill, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Joshua Zeidner is a Hematologist Oncology specialist and a Hematologist in Chapel Hill, North Carolina. Dr. Zeidner is rated as a Distinguished provider by MediFind in the treatment of Chronic Myelomonocytic Leukemia (CMML). His top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Zeidner is currently accepting new patients.

His clinical research consists of co-authoring 73 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles and participated in 3 clinical trials in the study of Chronic Myelomonocytic Leukemia (CMML).

Specialties
Hematology Oncology
Hematology
Oncology
Hospital Affiliations
Unc Hospitals
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
FirstCarolinaCare
  • HMO
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
101 Manning Dr, Chapel Hill, NC 27514

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Phase Ib/II Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Relapsed/Refractory CD30+ Hodgkin's Lymphoma and CD30+ Non-Hodgkin's Lymphoma
Phase Ib/II Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Relapsed/Refractory CD30+ Hodgkin's Lymphoma and CD30+ Non-Hodgkin's Lymphoma
Enrollment Status: Recruiting
Publish Date: October 14, 2025
Intervention Type: Biological
Study Drug: ATLCAR.CD30 cells
Study Phase: Phase 1/Phase 2
A Randomized, Open-label, Controlled, Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults With Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy
A Randomized, Open-label, Controlled, Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults With Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: October 08, 2025
Intervention Type: Drug
Study Drugs: Pevonedistat, Venetoclax, Azacitidine
Study Phase: Phase 2
NCI 10147: A Phase II Randomized Study of Topotecan/Carboplatin With or Without Veliparib in Advanced Myeloproliferative Disorders and Chronic Myelomonocytic Leukemia (CMML)
NCI 10147: A Phase II Randomized Study of Topotecan/Carboplatin With or Without Veliparib in Advanced Myeloproliferative Disorders and Chronic Myelomonocytic Leukemia (CMML)
Enrollment Status: Active_not_recruiting
Publish Date: June 24, 2025
Intervention Type: Drug
Study Drugs: Carboplatin, Topotecan, Topotecan Hydrochloride, Veliparib
Study Phase: Phase 2
A Phase 1b Study of the Anti-PD1 Antibody Pembrolizumab in Combination With the Histone Deacetylase Inhibitor, Entinostat for Treatment of Patients With Myelodysplastic Syndromes After DNA Methyltransferase Inhibitor Therapy Failure
A Phase 1b Study of the Anti-PD1 Antibody Pembrolizumab in Combination With the Histone Deacetylase Inhibitor, Entinostat for Treatment of Patients With Myelodysplastic Syndromes After DNA Methyltransferase Inhibitor Therapy Failure
Enrollment Status: Completed
Publish Date: March 25, 2025
Intervention Type: Drug, Biological
Study Drugs: Entinostat, Pembrolizumab
Study Phase: Phase 1
A Phase 1b Trial of Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Patients With Hematological Malignancies
A Phase 1b Trial of Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Patients With Hematological Malignancies
Enrollment Status: Terminated
Publish Date: January 17, 2025
Intervention Type: Drug
Study Drugs: Magrolimab, Azacitidine
Study Phase: Phase 1
A Phase 1/1b Study of Pevonedistat in Combination With Select Standard of Care Agents in Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Acute Myelogenous Leukemia, or Advanced Solid Tumors With Severe Renal Impairment or Mild or Moderate Hepatic Impairment
A Phase 1/1b Study of Pevonedistat in Combination With Select Standard of Care Agents in Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Acute Myelogenous Leukemia, or Advanced Solid Tumors With Severe Renal Impairment or Mild or Moderate Hepatic Impairment
Enrollment Status: Completed
Publish Date: September 05, 2024
Intervention Type: Drug
Study Drugs: Azacitidine, Pevonedistat, Docetaxel, Paclitaxel, Carboplatin
Study Phase: Phase 1
A Phase 1, Open-label, Dose-escalation, Safety and Biomarker Prediction of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
A Phase 1, Open-label, Dose-escalation, Safety and Biomarker Prediction of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Enrollment Status: Completed
Publish Date: November 15, 2023
Intervention Type: Drug
Study Phase: Phase 1
Phase 2, Randomized, Biomarker-driven Clinical Study in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With MCL-1 Dependence ≥30%
Phase 2, Randomized, Biomarker-driven Clinical Study in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With MCL-1 Dependence ≥30%
Enrollment Status: Terminated
Publish Date: November 15, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2, Open-label, Randomized, Two-stage Clinical Study of Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia Following Treatment With Venetoclax Combination Therapy
A Phase 2, Open-label, Randomized, Two-stage Clinical Study of Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia Following Treatment With Venetoclax Combination Therapy
Enrollment Status: Terminated
Publish Date: November 09, 2023
Intervention Type: Drug
Study Drugs: Alvocidib, Cytarabine
Study Phase: Phase 2
A Phase 1b/2, Open-label Clinical Study to Determine Preliminary Safety and Efficacy of Alvocidib When Administered in Sequence After Decitabine or Azacitidine in Patients With MDS
A Phase 1b/2, Open-label Clinical Study to Determine Preliminary Safety and Efficacy of Alvocidib When Administered in Sequence After Decitabine or Azacitidine in Patients With MDS
Enrollment Status: Terminated
Publish Date: November 09, 2023
Intervention Type: Combination product
Study Drugs: Alvocidib, Decitabine, Azacitidine
Study Phase: Phase 1/Phase 2
A Phase I Study of Pomalidomide Given at the Time of Lymphocyte Recovery Following Induction Timed Sequential Chemotherapy With Cytarabine, Daunorubicin and Etoposide (AcDVP16) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk MDS
A Phase I Study of Pomalidomide Given at the Time of Lymphocyte Recovery Following Induction Timed Sequential Chemotherapy With Cytarabine, Daunorubicin and Etoposide (AcDVP16) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk MDS
Enrollment Status: Completed
Publish Date: October 14, 2020
Intervention Type: Drug, Other
Study Phase: Phase 1
View 10 Less Clinical Trials

73 Total Publications

Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML.
Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 12, 2025
Similar Doctors
Distinguished in Chronic Myelomonocytic Leukemia (CMML)
Dr. Ellen M. Willard
Hematology Oncology | Hematology | Oncology
Distinguished in Chronic Myelomonocytic Leukemia (CMML)
Dr. Ellen M. Willard
Hematology Oncology | Hematology | Oncology
220 Page Rd, 
Pinehurst, NC 
 (53.2 miles away)
910-715-3500
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Ellen Willard is a Hematologist Oncology specialist and a Hematologist in Pinehurst, North Carolina. Dr. Willard is rated as a Distinguished provider by MediFind in the treatment of Chronic Myelomonocytic Leukemia (CMML). Her top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Richter Syndrome, and Chronic Myelomonocytic Leukemia (CMML). Dr. Willard is currently accepting new patients.

Advanced in Chronic Myelomonocytic Leukemia (CMML)
Dr. Daniel R. Richardson
Hematology | Oncology
Advanced in Chronic Myelomonocytic Leukemia (CMML)
Dr. Daniel R. Richardson
Hematology | Oncology

University Of North Carolina At Chapel Hill

101 Manning Dr, 
Chapel Hill, NC 
 (0.1 miles away)
984-974-1000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Daniel Richardson is a Hematologist and an Oncologist in Chapel Hill, North Carolina. Dr. Richardson is rated as a Distinguished provider by MediFind in the treatment of Chronic Myelomonocytic Leukemia (CMML). His top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), Acute Myeloblastic Leukemia without Maturation, and Bone Marrow Aspiration. Dr. Richardson is currently accepting new patients.

Advanced in Chronic Myelomonocytic Leukemia (CMML)
Dr. Alan D. Kritz
Hematology Oncology | Hematology | Oncology
Advanced in Chronic Myelomonocytic Leukemia (CMML)
Dr. Alan D. Kritz
Hematology Oncology | Hematology | Oncology

Rex Hospital Inc

4420 Lake Boone Trl, 
Raleigh, NC 
 (20.5 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Alan Kritz is a Hematologist Oncology specialist and a Hematologist in Raleigh, North Carolina. Dr. Kritz is rated as a Distinguished provider by MediFind in the treatment of Chronic Myelomonocytic Leukemia (CMML). His top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Multiple Myeloma, and Paget Disease of the Breast. Dr. Kritz is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Zeidner's expertise for a condition
ConditionClose
View All 27 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile